← Leaderboards
Webster L Santos
University Of Virginia
$7,267,557
Attributed
$12,546,410
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,546,410 · 9
By mechanism
R01$11,674,035 · 6
R21$440,030 · 1
R41$301,373 · 1
F32$130,972 · 1
Top collaborators
- Kevin R Lynch15 shared
- Kyle Lee Hoehn4 shared
- Alban P Gaultier1 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Kevin R Lynch$18,485,029
- James Pepper Bennett$2,762,528
- Shayn Peirce-Cottler$6,432,623
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsPropertyPathway InteractionsClinicProteinsDrug KineticsLeadCellsProgramsIn VivoBaseOralAnimal ModelClinical TrialsAffectInnovationDoseBiologyBloodInhibitor/AntagonistIn VitroSignal TransductionSphingosine 1-PhosphateTissues
Grant awards (29)
Blockade of S1P pathway for renal fibrosis therapy$572,063
R01 · FY2025 · DK · contact PI
Blockade of S1P pathway for renal fibrosis therapy$616,104
R01 · FY2024 · DK · contact PI
Therapeutic Mitochondrial Uncouplers$520,721
R01 · FY2024 · DK · contact PI
Controlling the flux of sphingosine-1-phosphate in vivo$689,462
R01 · FY2023 · AI
Therapeutic Mitochondrial Uncouplers$542,417
R01 · FY2023 · DK · contact PI
SPNS2 inhibitors as renal fibrosis therapy$301,373
R41 · FY2023 · DK · contact PI
Controlling the flux of sphingosine-1-phosphate in vivo$689,462
R01 · FY2022 · AI
Therapeutic Mitochondrial Uncouplers$542,417
R01 · FY2022 · DK · contact PI
Controlling the flux of sphingosine-1-phosphate in vivo$689,462
R01 · FY2021 · AI
Therapeutic Mitochondrial Uncouplers$576,086
R01 · FY2021 · DK · contact PI
Discovering new therapies to promote myelin repair$440,030
R21 · FY2021 · NS
Controlling the flux of sphingosine-1-phosphate in vivo$689,812
R01 · FY2020 · AI
MD-PHAR Controlling sphingosine 1-phosphate synthesis and trafficking$90,940
R01 · FY2020 · GM
Controlling the flux of sphingosine-1-phosphate in vivo$720,889
R01 · FY2019 · AI
Controlling sphingosine 1-phosphate synthesis and trafficking$448,536
R01 · FY2019 · GM
Controlling sphingosine 1-phosphate synthesis and trafficking$527,689
R01 · FY2018 · GM
Controlling sphingosine 1-phosphate synthesis and trafficking$527,689
R01 · FY2017 · GM
Controlling sphingosine 1-phosphate synthesis and trafficking$542,189
R01 · FY2016 · GM
In Vivo Probes of Sphingosine Kinase Function$368,198
R01 · FY2015 · GM · contact PI
In Vivo Probes of Sphingosine Kinase Function$374,885
R01 · FY2014 · GM · contact PI
RNA As A Therapeutic Target$312,376
R01 · FY2014 · GM · contact PI
In Vivo Probes of Sphingosine Kinase Function$388,656
R01 · FY2013 · GM · contact PI
RNA As A Therapeutic Target$302,101
R01 · FY2013 · GM · contact PI
RNA As A Therapeutic Target$298,330
R01 · FY2012 · GM · contact PI
RNA As A Therapeutic Target$312,711
R01 · FY2011 · GM · contact PI
RNA As A Therapeutic Target$330,840
R01 · FY2010 · GM · contact PI
Peptide Morphing: Rational Design of Separase Inhibitors$48,296
F32 · FY2005 · GM
Peptide Morphing: Rational Design of Separase Inhibitors$42,976
F32 · FY2004 · GM
Peptide Morphing: Rational Design of Separase Inhibitors$39,700
F32 · FY2003 · GM